Interest is rising in psychedelics to treat depression and the FDA released new research guidelines

When Jason Wallach started researching psychedelic compounds just over a decade ago, he expected he would spend his career laboring in obscurity. Now the Food and Drug Administration is taking new steps to advise scientists studying these drugs, a sign that the federal government, and society at large, are paying closer attention to his rapidly-growing field of research. Wallach, a professor at Philadelphia's St. Joseph's University, develops psychedelic drugs to treat depression and other mental illnesses. In June, for the first time, the FDA released a draft list of guidelines for conducting...